IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.858
AS - Asia 3.338
NA - Nord America 2.911
SA - Sud America 732
Continente sconosciuto - Info sul continente non disponibili 265
AF - Africa 65
OC - Oceania 6
Totale 11.175
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.752
RU - Federazione Russa 2.261
SG - Singapore 1.117
CN - Cina 1.084
BR - Brasile 594
HK - Hong Kong 339
IT - Italia 339
RO - Romania 339
VN - Vietnam 321
SE - Svezia 258
DE - Germania 172
FR - Francia 152
BD - Bangladesh 136
GB - Regno Unito 104
IN - India 82
CA - Canada 72
AR - Argentina 59
FI - Finlandia 54
MX - Messico 41
ID - Indonesia 40
IQ - Iraq 39
AT - Austria 34
PL - Polonia 30
TR - Turchia 28
ES - Italia 27
JP - Giappone 26
NL - Olanda 25
ZA - Sudafrica 25
EC - Ecuador 21
CO - Colombia 18
IE - Irlanda 15
MY - Malesia 15
PK - Pakistan 15
PH - Filippine 13
SA - Arabia Saudita 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
LT - Lituania 10
NP - Nepal 10
TN - Tunisia 10
VE - Venezuela 10
HN - Honduras 8
PY - Paraguay 8
UA - Ucraina 8
CL - Cile 7
CZ - Repubblica Ceca 7
DO - Repubblica Dominicana 6
JM - Giamaica 6
MA - Marocco 6
PE - Perù 6
UY - Uruguay 6
AU - Australia 5
BE - Belgio 5
KE - Kenya 5
OM - Oman 5
SV - El Salvador 5
AZ - Azerbaigian 4
BB - Barbados 4
CR - Costa Rica 4
DZ - Algeria 4
IL - Israele 4
BH - Bahrain 3
CH - Svizzera 3
CI - Costa d'Avorio 3
NG - Nigeria 3
NI - Nicaragua 3
PT - Portogallo 3
TH - Thailandia 3
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
IR - Iran 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
TT - Trinidad e Tobago 2
UG - Uganda 2
AL - Albania 1
BG - Bulgaria 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
JO - Giordania 1
KI - Kiribati 1
KR - Corea 1
LB - Libano 1
Totale 10.903
Salva come PNG Salva come JPEG
Città #
Singapore 550
Moscow 455
Dallas 344
Ashburn 339
Hong Kong 335
San Jose 317
New York 179
Council Bluffs 178
Shanghai 165
Beijing 153
Hefei 140
Lauterbourg 121
Ho Chi Minh City 108
Lawrence 95
Milan 95
Princeton 95
Los Angeles 82
Hanoi 77
Santa Clara 57
Munich 55
São Paulo 47
Boardman 44
Nuremberg 42
Orem 41
Denver 34
Helsinki 34
Warsaw 29
Chennai 26
London 26
Tokyo 26
Montreal 24
Guangzhou 23
Atlanta 20
Frankfurt am Main 20
Rome 20
Brooklyn 19
Da Nang 19
Houston 19
Vienna 18
Buffalo 17
Manchester 17
Baghdad 16
Dublin 16
Stockholm 16
Chicago 15
Mexico City 15
Phoenix 15
Poplar 15
Toronto 15
Seattle 14
Shenzhen 14
Washington 14
Brasília 13
Johannesburg 13
Rio de Janeiro 13
Amsterdam 12
Ankara 12
Curitiba 12
Falkenstein 12
Turku 12
Biên Hòa 11
Tashkent 11
Boston 10
Charlotte 10
Guayaquil 10
Barnet 9
Haiphong 9
Las Vegas 9
Memphis 9
Mumbai 9
Belo Horizonte 8
Kuala Lumpur 8
Madrid 8
Pietra Ligure 8
Porto Alegre 8
Pune 8
Querétaro 8
San Francisco 8
Sorocaba 8
Bologna 7
Monza 7
Columbus 6
Goiânia 6
Hải Dương 6
Lappeenranta 6
New Delhi 6
Ottawa 6
Quanzhou 6
Salvador 6
Tianjin 6
Asunción 5
Brussels 5
Buenos Aires 5
Campinas 5
City of London 5
Erbil 5
Ha Long 5
Hangzhou 5
Istanbul 5
Jakarta 5
Totale 5.056
Salva come PNG Salva come JPEG
Nome #
Monkeypox in a patient with undifferentiated connective tissue disease 253
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 252
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 212
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 197
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 184
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 179
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 136
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 130
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 124
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 123
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 119
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 119
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 117
Achieving virological control in pan-resistant HIV-1 infection: A case series 115
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 115
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 115
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 113
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 111
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 110
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 107
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 107
Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 105
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 105
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 104
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 102
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 101
Bictegravir 101
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 99
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 99
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 99
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 98
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 98
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 97
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 97
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 96
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 94
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 93
Disseminated Mycobacterium chimaera infection favoring the development of Kaposi’s sarcoma: a case report 92
Inflammation burden score in multidrug-resistant HIV-1 infection 90
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 90
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 89
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 88
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 88
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 87
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 87
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 87
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 87
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 86
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 86
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 84
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 84
Addressing late HIV presentation: the current knowledge and unmet needs 79
Darunavir for the treatment of HIV infection 78
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 77
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 75
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 75
An evaluation of cabotegravir for HIV treatment and prevention 74
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 74
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 74
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 73
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 72
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 71
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 71
Is shorter duration of antibiotic treatment feasible in patients with cardiac implantable electronic device infections undergoing device removal? A propensity-adjusted analysis of a 10-year retrospective cohort 71
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 70
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 70
Cervical cancer risk in women living with HIV across four continents: A multicohort study 69
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 69
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 68
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 67
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 66
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 66
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 66
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 66
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 65
Immune recovery and T cell subset analysis during effective treatment with maraviroc 63
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 60
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 60
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 60
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 60
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 60
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 60
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests" 59
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study 59
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 59
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 58
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 58
PRESTIGIO RING: “Persistent low-level viremia with preserved immunological profile in people with multidrug-resistant HIV: is it time to defer switching?” 58
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 57
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 57
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 56
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 56
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 56
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 56
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 56
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 55
Influence of gender in predicting CCR5 coreceptor usage 55
Impact of analytical treatment interruption on burden and diversification of hiv peripheral reservoir: A pilot study 55
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors 54
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 54
Totale 8.998
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.207
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.207
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202278 0 0 0 18 9 9 2 13 7 4 9 7
2022/2023494 206 103 28 4 8 42 43 36 19 2 1 2
2023/2024463 11 18 81 31 49 121 6 43 1 4 27 71
2024/20252.159 194 25 42 64 89 164 661 167 250 132 114 257
2025/20267.296 523 497 480 903 538 243 615 581 1.941 448 280 247
2026/2027593 256 337 0 0 0 0 0 0 0 0 0 0
Totale 11.175